肾小球疾病患者的癌症发病率:一项人群水平研究
加拿大不列颠哥伦比亚省2000–2020年纳入4039例确诊肾小球肾炎(GN)成人,中位随访7.8年,9.5%发生新发癌症;癌症发病率比一般人群高30%(SIR 1.3),40岁以下者近乎3倍(SIR 2.9),淋巴瘤、肾癌、结直肠癌和肺癌风险显著增加。
要点
- GN患者总体癌症风险较一般人群升高30%,40岁以下者升高近3倍。
- 淋巴瘤、肾癌、结直肠癌和肺癌发病率显著增加。
- 年龄、男性、基线eGFR和GN病理类型与癌症风险独立相关。
核心结论
- GN患者癌症风险显著高于一般人群,年轻患者风险尤为突出。
研究设计与样本
- 回顾性观察性队列研究,纳入加拿大不列颠哥伦比亚省2000–2020年病理登记确诊的4039例成人GN患者。
主要发现
- 中位随访7.8年期间,384例(9.5%)发生新发癌症,20年癌症风险为23%。
- 癌症发病率比一般人群高30%(SIR 1.3 [95% CI 1.2–1.4])。
- 40岁以下患者风险近乎一般人群3倍(SIR 2.9 [95% CI 1.6–4.6])。
- 淋巴瘤(SIR 3.5)、肾癌(SIR 2.6)、结直肠癌(SIR 2.4)和肺癌(SIR 1.5)发病率显著增加。
- 年龄、男性、基线eGFR和GN病理类型与癌症风险独立相关。
临床怎么用
- 应提高对GN患者癌症风险的认知,尤其关注40岁以下通常不在常规筛查范围内的人群。
- 可考虑针对淋巴瘤、肾癌、结直肠癌和肺癌制定个体化筛查与预防策略。
局限性
- 缺乏免疫抑制治疗数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONAL & OBJECTIVE: People with glomerulonephritis (GN) may be at an increased risk of cancer, but existing studies have not accurately clarified the cancer risk in patients with GN. A better understanding of these risks may inform cancer screening strategies and identify potentially modifiable risk factors. This study identified risk factors for cancer among Canadian patients with GN. STUDY DESIGN: Retrospective observational cohort study. SETTING & PARTICIPANTS: Adults with diagnosed GN (n = 4,039) identified using a centralized pathology registry in British Columbia, Canada, between 2000 and 2020. EXPOSURE: Known cancer risk factors, including age, sex, ethnicity, smoking, alcohol abuse, obesity, diabetes, dyslipidemia, hypertension, and cardiovascular disease as well as GN-related potential risk factors, including GN disease type, estimated glomerular filtration rate (eGFR), and level of proteinuria. OUTCOME: All-cause cancer, excluding non-melanoma skin cancer. ANALYTICAL APPROACH: Standardized incidence ratios (SIRs) were calculated using an age- and sex-matched general population. The time to the first cancer event was modeled using a cause-specific hazards model, with death considered as a competing event. RESULTS: The mean age of the cohort was 51 years, and 52% of the participants were male. During a median of 7.8 years of follow-up, 384 patients (9.5%) developed de novo cancer. The 20-year cancer risk was 23%, with an incidence rate 30% higher than the general population (SIR, 1.3 [95% CI, 1.2-1.4]). The risk was most pronounced in patients younger than 40, almost 3-fold higher than in the general population (SIR, 2.9 [95% CI, 1.6-4.6]). Significant increases in cancer incidence were observed for lymphoma (SIR, 3.5), kidney (SIR, 2.6), colorectal (SIR, 2.4), and lung cancers (SIR, 1.5). Elevated risk was observed both before and after the onset of end-stage kidney disease. Age, male sex, baseline eGFR, and GN disease type were independently associated with cancer risk. LIMITATIONS: The lack of immunosuppression data. CONCLUSIONS: Patients with GN have a substantially increased risk of cancer compared with the general population, particularly younger patients who are typically excluded from current screening programs. These findings suggest the need to raise awareness of the cancer risk among people with GN and may inform the further development of tailored cancer screening and prevention strategies, especially among younger adults with GN. PLAIN-LANGUAGE SUMMARY: People with glomerulonephritis (GN) are thought to be at an increased risk of cancer, but previous studies had limitations that limited the accuracy of the cancer risk estimates in this population. This study of 4,039 patients with GN found the incidence of cancer to be 30% higher than in the general population. Among patients under 40 years of age, the risk was nearly 3-fold. The types of cancers at increased risk were colorectal, lung, kidney, and lymphoma. These findings highlight the need to raise awareness of cancer risk in patients with GN and may inform further development of targeted screening and prevention strategies, particularly among younger adults.
引用
- Han J, Canney M, Zhao Y, et al. Cancer Incidence in People With Glomerular Disease: A Population-Level Study. Am J Kidney Dis. 2026. PMID: 41881381. doi:10.1053/j.ajkd.2025.11.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。